Pain modulation

PreclinicalSmall molecule

AAalborg University

Pain modulation is one of 3 small molecule programs targeting Local. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LocalUnknown status

LocalPreclinical

Unknown status

Competition

Competitive Landscape

3 competitors in Local

#DrugCompanyPhaseTrials

Growth Hormone

Pfizer

Preclinical

1 2

L-NMMA

NNational Heart, Lung, and Blood Institute (NHLBI)

Preclinical

1 3

Pain modulation

AAalborg University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Local1 trial

Assessment of Peripheral GABA Receptors for Local Pain Relief

Unknown status·—·N/A·NCT02928328·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Pain modulation. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pain modulation compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pain modulation. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Aalborg University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: AAalborg University

Pain modulation

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Local1 trial

References

Drug Info

Quick Facts

Related News